IBM closing research unit in China, Wall Street Journal reports
By Steve Gelsi
Move will reportedly affect 1,000 jobs and comes after IBM's revenue from China fell nearly 20% in 2023
IBM Corp. is shutting down its research and development department in China in a move that will affect 1,000 jobs, as technology companies continue moving out of the country, the Wall Street Journal reported Monday.
IBM (IBM) broke the news in a virtual meeting with employees in Asia, the newspaper reported.
Employees told the Journal that some of the jobs will move to other locations, such as Bengaluru, India.
An IBM China spokesperson did not comment, the newspaper said.
While China's economic growth has drawn in IBM and other companies, the government has been promoting domestic technology companies over U.S. companies, the report said.
IBM's revenue from China dropped by nearly 20% in 2023.
IBM's stock rose 0.3% in early trading on Monday.
Also read: Thousands of miles from Silicon Valley, this small country is building a booming tech sector
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-26-24 0947ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk